The British Society of Gastroenterology (BSG) has published guidelines on the diagnosis and management of Barrett’s oesophagus (BO), aiming to provide a practical and evidence-based resource for healthcare professionals. The guidelines were developed using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument and a systematic review of the literature up to December 2012. They address key issues such as the definition of BO, screening, surveillance, diagnosis of dysplasia, management of dysplasia and early cancer, and chemoprevention. The guidelines emphasize the importance of stratifying patients based on their estimated cancer risk using clinical and histopathological criteria. They recommend the use of minimum datasets for reporting endoscopic and pathological findings to improve communication between clinicians. Endoscopic therapy is advocated for high-grade dysplasia and early cancer, which should be performed in high-volume centres. The guidelines also highlight the need for regular follow-up after endoscopic therapy and the importance of considering patient perspectives in decision-making. The recommendations are graded based on the strength of the evidence, with Grade A being the strongest. The guidelines are intended to standardise and improve the management of BO and related neoplasia. They are expected to be reviewed in about 5 years, with specific sections possibly needing revision as new data emerge. The guidelines are available for consultation on the BSG website and will be reviewed by clinical services committees before publication. The guidelines also include a patient information sheet and tables to help practitioners acquire the minimum dataset of clinical information for optimal patient management. The guidelines are intended to be supplemented with endoscopic and histopathological images for educational purposes. The guidelines are expected to be disseminated through publication in the peer-reviewed journal Gut and through presentations at national conferences and training courses. The guidelines are based on a comprehensive review of the literature and take into account the benefits and risks for the population and national health system, as well as patient perspectives. The guidelines are intended to be used by gastroenterologists, physicians, nurse practitioners, and members of multidisciplinary teams (MDTs) who make decisions about the management of patients with BO and related neoplasia. The guidelines are expected to be reviewed in about 5 years, with specific sections possibly needing revision as new data emerge. The guidelines are based on a comprehensive review of the literature and take into account the benefits and risks for the population and national health system, as well as patient perspectives. The guidelines are intended to be used by gastroenterologists, physicians, nurse practitioners, and members of multidisciplinary teams (MDTs) who make decisions about the management of patients with BO and related neoplasia.The British Society of Gastroenterology (BSG) has published guidelines on the diagnosis and management of Barrett’s oesophagus (BO), aiming to provide a practical and evidence-based resource for healthcare professionals. The guidelines were developed using the Appraisal of Guidelines for Research and Evaluation (AGREE II) instrument and a systematic review of the literature up to December 2012. They address key issues such as the definition of BO, screening, surveillance, diagnosis of dysplasia, management of dysplasia and early cancer, and chemoprevention. The guidelines emphasize the importance of stratifying patients based on their estimated cancer risk using clinical and histopathological criteria. They recommend the use of minimum datasets for reporting endoscopic and pathological findings to improve communication between clinicians. Endoscopic therapy is advocated for high-grade dysplasia and early cancer, which should be performed in high-volume centres. The guidelines also highlight the need for regular follow-up after endoscopic therapy and the importance of considering patient perspectives in decision-making. The recommendations are graded based on the strength of the evidence, with Grade A being the strongest. The guidelines are intended to standardise and improve the management of BO and related neoplasia. They are expected to be reviewed in about 5 years, with specific sections possibly needing revision as new data emerge. The guidelines are available for consultation on the BSG website and will be reviewed by clinical services committees before publication. The guidelines also include a patient information sheet and tables to help practitioners acquire the minimum dataset of clinical information for optimal patient management. The guidelines are intended to be supplemented with endoscopic and histopathological images for educational purposes. The guidelines are expected to be disseminated through publication in the peer-reviewed journal Gut and through presentations at national conferences and training courses. The guidelines are based on a comprehensive review of the literature and take into account the benefits and risks for the population and national health system, as well as patient perspectives. The guidelines are intended to be used by gastroenterologists, physicians, nurse practitioners, and members of multidisciplinary teams (MDTs) who make decisions about the management of patients with BO and related neoplasia. The guidelines are expected to be reviewed in about 5 years, with specific sections possibly needing revision as new data emerge. The guidelines are based on a comprehensive review of the literature and take into account the benefits and risks for the population and national health system, as well as patient perspectives. The guidelines are intended to be used by gastroenterologists, physicians, nurse practitioners, and members of multidisciplinary teams (MDTs) who make decisions about the management of patients with BO and related neoplasia.